<DOC>
	<DOCNO>NCT00008203</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Biological therapy may interfere growth cancer cell . It yet know post-transplant biological therapy regimen effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness cyclosporine interferon gamma interleukin-2 follow combination chemotherapy bone marrow peripheral stem cell transplantation woman stage II stage III breast cancer .</brief_summary>
	<brief_title>Comparison Biological Therapies Following Combination Chemotherapy Bone Marrow Peripheral Stem Cell Transplantation Women With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response , disease-free survival ( DFS ) , overall survival woman high-risk stage II III breast cancer treat high-dose cyclophosphamide , thiotepa , carboplatin autologous marrow and/or peripheral blood stem cell transplantation . - Determine safety immunomodulation consist cyclosporine interferon gamma versus low-dose interleukin-2 patient population . - Determine parameter associate immune activation autologous graft-versus-host disease . - Determine immunomodulation regimen efficacious respect DSF . OUTLINE : This randomize study . Patients stratify accord stage ( II v III ) , age , lymph node status , inflammatory histology . Patients randomize one two immunomodulation arm . Autologous harvest least 1 million CD34+ cell /kg 400 million mononuclear cells/kg must achieve . All patient receive cyclophosphamide IV continuously thiotepa IV continuously 96 hour day -6 -3 carboplatin IV 5 hour daily day -6 -3 . Patients undergo autologous bone marrow and/or peripheral blood stem cell transfusion day 0 . - Arm I : Patients receive cyclosporine IV 4 hour twice day , begin day 0 continue discharge hospital , interferon gamma subcutaneously ( SC ) every 2 day day 7-28 . - Arm II : Patients receive interleukin-2 SC daily 28 day follow recovery blood count . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year annually 5 year . PROJECTED ACCRUAL : A total 70 patient ( 30 stage II disease 40 stage III disease ) accrue 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Stage II least 10 lymph node involve malignancy OR Stage III ( T3bT4 , N2 N3 , M0 ) Ineligible high priority national institutional study No metastasis brain ( confirmed CT MRI ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 physiologic 65 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2 time normal Renal : Creatinine le 1.5 time normal Cardiovascular : LVEF least 45 % Other : HIV negative Not pregnant nurse PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 cycle prior chemotherapy require Stage II patient must complete 46 course doxorubicin and/or taxolbased adjuvant chemotherapy Stage III patient must achieve complete partial response 46 course doxorubicin and/or taxolbased induction chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2003</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>